Full-Time
Sales Support
Clinical Solution Consultant-CV Ultrasound, Colorado/Wyoming
Posted on 5/30/2026
Philips
Healthcare technology for diagnosis, care, wellness
Compensation Overview
$125k - $155k/yr
No H1B Sponsorship
Fort Collins, CO, USA + 1 more
More locations: Denver, CO, USA
In Person
Must reside in or within commuting distance to the Colorado/Wyoming territory; relocation not offered.
 Sales & Account Management (1) |
|---|
- Five or more years of experience in Registered Diagnostic Sonographer (RDCS) or equivalent registry; Teaching or in-service experience.
- Bachelor's degree or equivalent experience/registries listed above and below.
- Strong communication, customer service, training, and motivational skills.
- You must be able to successfully perform the minimum Physical, Cognitive and Environmental job requirements for this Sales position (as per the linked job requirements).
- US work authorization is a precondition of employment; sponsorship for work-authorized visa is not available now or in the future.
- Willingness to travel up to 50% or more; this is a field-based role.
- Meet or exceed assigned annual objective and target for equipment and revenue by collaborating with CV Ultrasound Account Managers to develop and execute a strategy to meet financial targets.
- Provide pre-sale and post-sale product support and customer follow up maintenance for the entire CV Ultrasound Product portfolio.
- Schedule and perform product demonstrations, both onsite and virtually, in coordination with partnered CV Ultrasound Account Manager(s) to support the assigned territory and assist other territories as needed.
- Post product demonstration, work closely with partnered CV Account Managers to ensure Philips is selected as clinical vendor of choice.
- Exhibit superior technical, clinical and presentation skills.
- Philips Ultrasound product knowledge and additional registries, highly preferred.
- In-depth clinical knowledge and proficient skills in cardiovascular disease and cardiovascular multi-segment environments.
- Any additional registries knowledge beyond RDCS would be considered desirable.
Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.
Company Size
N/A
Company Stage
IPO
Headquarters
Andover, Minnesota
Founded
1891
Simplify's Take
What believers are saying
- Remote patient monitoring growth expands demand for Philips' connected-care and home-care offerings.
- The 2.5 billion lives target supports scale-focused partnerships in underserved and developed markets.
- Hospital deployments like HealthAlliance validate demand for faster imaging and tighter monitoring integration.
What critics are saying
- Respironics recall settlements and remediation continue pressuring cash flow and reputation.
- Imaging rivals like GE HealthCare compress pricing and complicate large hospital contract wins.
- Remote-monitoring competitors from Medtronic and Abbott threaten Philips' subscription-style connected-care adoption.
What makes Philips unique
- Philips spans diagnosis, treatment, connected care, and personal health across the care continuum.
- It leads in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics.
- Its strategy emphasizes integrated solutions and long-term partnerships, not standalone device sales.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.
Register now for your free virtual pass to the Low-Code/No-Code Summit this November 9. Hear from executives from Service Now, Credit Karma, Stitch Fix, Appian, and more. Learn more. Philips Norelco is creating an interactive metaverse experience called Shavetopia in Roblox, based around the Movember trend. For anyone who doesn’t know what that is, Movember is where people grow facial hair for the entire month of November. The portmanteau comes from adding the word mustache to the name of the month